"Synthetic Biology: ENGINEERING LIFE"



- There are many definitions of synthetic biology and each have varying ethical, legal, social and economic implications
- One general definition of synthetic biology is; the design and construction of new biological parts, devices, and systems and the re-design of existing, natural biological systems for useful purposes

Synthetic biology contains elements of nanotechnology and biotechnology

- Synthetic biology can be a technology based on the traditional genetic code
- Or it can be based on artificial genetic code, artificial amino acids and proteins.
- It can also be the creation of biological system with non-biological material or making of non-biological system with biological material.

"Synthetic Biology: ENGINEERING LIFE"

Mainly developed at the USA, with some minor disperse efforts. In Europe

Bioscience: From Discovery to Creation

CLASSICAL BIOLOGY Qualitative, Descriptive (Linnean)

Quantitative, Predictive Models

SYNTHETIC BIOLOGY Engineering of Living Systems

Integration of Biological & Non-biological Components





analysis Modelling of complex states

BIOSYSTEMS

Engineering Nanoscale technology/metrology Electronics Process control theory Systems modelling Biology poses unique challenges for engineering



We need new engineering rules to control or utilize these properties.

SYNTHETIC BIOLOGY: ENGINEERING STANDARIZATION





Why now Synthetic Biology?

Why now?

- Advances in computing power
- Genomic sequencing
- Crystal structures of proteins
- Internet through-put
- **Holo**gical databases
- Diverse biological sampling/collection



How do advances in DNA synthesis affect synthetic biology?

Our capacity to assemble long stretches of DNA that approach the length of genomes has increased.

DNA synthesis is an enabling tool for construction of a genome of known sequence, in the absence of a **physical** template.

The genomes of known viruses have been synthesized.

Improved DNA synthesis does not address the essential Issue of how to synthesize an organism with predefined, useful altered properties.

NEW TOOLS FOR GENOME ENGINEERING

Precision scalpels for genome engineering





www.smartcell.crg.es



COMPUTER TOOLS TO SIMULATE BIOLOGICAL SYSTEMS

$P + A \xrightarrow[k_{on,A}]{k_{on,A}} PA$	(1)	$P + C \xrightarrow[k_{on,C}]{k_{off,C}} PC$	(17)
PA → PB + A	(2)	$PC \xrightarrow{k_{in}} PD + C$	(18)
$PB \xrightarrow{k_{transcr}} M + P + B$	(3)	PD $\xrightarrow{k_{transcr}}$ N + P + D	(19)
M ^{−k} transt T	(4)	N ^{_k} transl→ G	(20)
M —kdeg_M Ø	(5)	$N \xrightarrow{k_{deg_N}} \emptyset$	(21)
$P + Z \xrightarrow{k_{on,Z}} PZ$	(6)	T + aTc kot.Ta1 TaTc	(22)
$PY \xrightarrow{k_{in}} PY + Z$	(7)	TaTc + aTc $\stackrel{k_{on_Ta2}}{\underset{k_{on_Ta2}}{\longleftarrow}}$ T(aTc) ₂	(23)
$PY \xrightarrow{k_{transcr}} P + Y$	(8)	$T + C \xrightarrow{k_{onT6}}{k_{onT6}} TC$	(24)
$T + A \xrightarrow[k_{on_{-}T1}]{k_{on_{-}T1}} TA$	(9)	TaTc + C	(25)
TaTc + A	(10)	$T(aTc)_2 + C \xrightarrow[k_{on_T8}]{k_{off_T8}} T(aTc)_2 C$	(26)
$T(aTc)_2 + A \xrightarrow{k_{on_1}T_3}{k_{on_2}T_3} T(aTc)_2 A$	(11)	TC + aTc	(27)
TA + aTc $\xrightarrow{k_{on_{T4}}}$ TaTcA	(12)	TaTcC + aTc $\frac{k_{on_{T10}}}{k_{off_{T10}}}$ T(aTc) ₂ C	(28)
TaTcA + aTc $\frac{k_{on_1T5}}{k_{off_1T5}}$ T(aTc) ₂ A	(13)	G [⊥] deg_G Ø	(29)
T ø	(14)		
TaTc ^k dog_⊺→ aTc	(15)		

(16)

T(aTc)₂ ^{k_{deg_T} → 2 aTc}

Successful examples for structure-based predictions and protein design



Kiel et al., J Mol Biol, **2005** Kiel et al., J Mol Biol, revised, **2007**



Arnould et al., J. Mol. Biol, 2006



Kolsch et al., Science, 2007



Musi et al., Protein Sci, 2006

Kempkens, O., E. Medina, et al. (2006)

Van der Sloot, et al, PNAS, 2006

Defining the Rule Sets for Biological Design, Assembly and Function

- common genetic (digital) code in all life forms
- genomes encode a limited series of structural building blocks (protein motifs and programmed assembly)
- combinatorial assembly of protein building blocks generates extravagant structural and functional diversity



Playing with Synthetic Biology

Engineering of Circuits

What sorts of modules have been made by synthetic biologists?

pSC101

origin

kan

GFP

ColE1

λPr

lacl-lite

λ cl — Lacl

ทัก-ลอบ

Oscillators





Engineering of Circuits Building a sender & receiver







Basu et al (2005) Nature, 434, 1130

Engineering of Circuits Bacterial photography



Synechosystis: Photoreceptor, Phytochrome synthesis genes (ho1, pcyA) E. coli: osmotic shock response circuit (ompC), β -galactosidase

Levskaya et al (2005) Nature,

We need more Parts

Biological Design: "Endless Forms Most Beautiful": Limitless Diversity From Combinatorial Assemblies of Limited Building Blocks



Metagenomics: Sampling the Extravagant Functional Diversity of Microorganisms

- estimated 100 billion microbial species
- only 6000 species cultivated and characterized
- massive repertoire of uncharacterized genes/proteins/metabolomes
- metagenomic sampling
 - mass screening of complete genomes of unknown/unculturable organisms
 - high throughput profiling to identify transfer of gene(s) with desired function into 'universal acceptor' organisms

Ecogenomics: Mapping the Extraordinary Genomic Diversity and Biosynthetic Capabilities of Microbial Life









Exploring Biospace: Iterative Selection of Novel Variants for Substantial Functional Performance Improvements Versus Naturally Occurring "Parent System"



Activity Versus Starting Material



Possible applications of Synthetic Biology

Synthetic Biology: An Emerging Technology with Diverse Industrial Applications



Biological Sensor Systems for Environmental Monitoring and Ecosystem Status

Genetically-Engineered Arabidopsis thaliana Change-Color when Exposed to Landmine Degradation Products



Aresa Biotection, Demark

Engineering Sentinel Organisms as Environmental Sensors



D. N. Dhanasekaran et al (2007) Nature Chem. Biol. DOI: 10.1038/nchembio882

Directed Evolution and Design of Novel Enzymes for Catalysis of Lignocellulosic Biomass



- cellulosic energy crops
- agricultural, forestry and mill residues
- food processing residues
- municipal solid waste
- non-recycled paper
- construction and demolition wood



Production of Biodiesel from Biomass: A Widely Differing Yield Spectrum*			
Source	Yield		
	US gal/acre	L/Km ²	
● Soybean	40-50	35-45,000	
 Rapeseed 	110-145	100-130,000	
Mustard	140	130,000	
 Jatropha 	175	160,000	
● Palm oil	650	580,000	
 Photosynthetic Microbes 	10-20,000	9-18,000,000	
* http://en.wikipedia.org/wiki/Biodiesel			

Biofuels



- First generation
 - Food feedstock: sugar, starch, vegetable oil or animal fats using conventional technology (food for fuel debate)
 - Fuel types: vegetable oil, biodiesel, butanol, ethanol, syngas
- Second generation (Needs Synthetic Biology)
 - Non food crop feedstock: cellulose, waste biomass: wheat, corn, wood
 - Fuel types: biohydrogen, biomethanol, DMF, bio-DME, Fischer-Tropsch diesel, biohydrogen diesel, mixed alcohols and wood diesel
- Third generation (Needs Synthetic Biology)
 - Algae feedstock
- Fourth generation (Needs Synthetic Biology)
 - CO_2 feedstock: CO_2 converted to methane by bacteria



Building a Super H₂ Producer







- well characterized, tractable genome
 siting flexibility for trait enhancement
- no celluose

THE biodesign INSTITUTE

- compositional homogeneity
- rapid assay of genetic modifications
- no or limited transport costs
- CO₂ fixation

THE biodesign institute

Synthetic Biology and Engineering Enhanced Traits in Food, Feed and Fiber Products



Synthetic Biology and Novel Industrial Process Chemistry


Microbial Genomics and Synthetic Biology: New Technology Platforms for Bioremediation and Improved Efficiency of Wastestream Management



Bio-Inspired Engineering: Removal of Perchlorate Contamination by Chemical Reduction by Biofilms of Hydrogen Producing Bacteria

- ✓ pilot scale project at La Puente, CA (400 L/min)
- ✓ influent: 25 mg/L of NO₃⁻ and 60 µg/L ClO₄⁻
- ✓ ≈ 95% removal of ClO₄-, from 60 µg/L to below the CA action level of 4 µg/L
- ✓ ≈ 98% NO₃⁻ removal of 25 mgN/L to ≈ 0.5mgNO₃⁻/L
- ✓ essentially 100% H₂ usage



Malaria

- 1.5-2.7 million
 people die of
 malaria every year
 - 90% of the victims are children
 - 40% of the world's population is at risk
- of ry year victims n world's
- Economists have proposed that malaria decreases the GDP of affected countries by as much as 50%.



Chloroquine-based drugs

- Most widely-used drugs to treat malaria
- Plasmodium in South America and Southeast Asia is largely resistant to chloroquine









Artemisinin-based drugs

- The current cost is approximately \$2.40.
 - Artemisinin adds \$1.00-1.50 to the cost for drugs
 - Most developing countries spend less than \$4/person/year on health care
- As many as 10-12 treatments are needed for each person annually
- World Health Organization estimates that 700 tons will be needed annually





Potential sources for artemisinin

- Agriculture
 - Efforts are under way to plant Artemisia annua around the world
- Chemical synthesis
 - A synthesis route is known but it is too complicated for economical production
- Microbial
 - Need all of the genes from the plant







atcttgtgat catcccaaga caaaaccaga gaaaaagacc tgtctgtttt tttaagaagt ctttatatta tttttttgt cggagaatct tataagcatg gcttcaggag gatcaaagtc ggcagcttc atgcttctga tgctgaatct tggtctctat ttcgtcatca ccatcatcgc ttcttgggct gttaatcacg gcatcgagag aactcgcgag tctggtaact aacaaagata acaactgatt aagtaacaat taatccaacg ttagaaaatg tcatcatcaa tcttctttt gtggtatttt gcagcgtcga cactgtcact tccggcgaag atattcccga tatacttccc ggtggggaac atggcgaccg gtttttcgt aatattcacg ttaatcgccg gcgtcgtcgg



Making a plant gene look like a microbial gene



atcttgtgat catcccaaga caaaaccaga gaaaaagacc tgtctgtttt tttaagaagt ctttatatta tttttttgt cggagaatct tataagcatg gctcaggag gatcaaagtc ggcagctttc atgcttctga tgctgaatct tggtctctat ttcgtcatca ccatcatcgc ttcttgggct gttaatcacg gcatcgagag aactcgcgag tctggtaact aacaaagata acaactgatt aagtaacaat taatccaacg ttagaaaatg tcatcatcaa tcttctttt gtggtatttt gcagcgtcga cactgtcact tccggcgaag atattcccga tatacttccc ggtggggaac atggcgaccg gttttttcgt aatattcacg ttaatcgccg gcgtcgtcgg













Artemisinin costs

Artesunate combination treatment

Current cost of drug \$2.25-2.50

Cost with new process \$.21/.12







Coding Capacity vs Physical Limitations



Towards "biobots": cancer invading bacteria



Vibrio fisheri: Quorum sensing (cell density sensing) E.coli: hypoxia responsive promotor (fdhF) Yersinia pseudotuberculosis: invasin (inv)

Anderson *et al* (2006) *J Mol Biol.* 355. 619

Perspectives and Ethics



What can synthetic biology deliver (in 5-10 years time)?



- anticipated powerful driver of industrial innovation and market disruption
- new aspirants, new cross-sector relationships and new markets
- the next era in the evolution of human mastery of the environment
 - agronomic, industrial, informational, genetic, biomimetic, designed life forms
 - enhancement and eugenics?

The End of the Darwinian Interlude

- early 'biotic' world
 - massive lateral gene transfer and 'loose' definition of species
 - rapid evolution as a communal affair
- the Darwinian interlude
 - majority period in evolution (3 billion plus) years
 - slow pace of change and species 'isolationism'
- synthetic biology
 - revival of pre-Darwinian era of horizontal gene transfer

Synthetic Biology: Inter-disciplinary Convergence and Complex Policy Issues



Synthetic Biology

- complex policy issues
- design of novel life forms and societal response
- dual-use applications
- public and media attitudes to perceived risks and benefits
- proactive, predictable, evidence-based regulatory frameworks

Key points raised in 2009 Samuel, Selgelid, Kerridge, <u>EMBO reports</u>

- Misuse for weapons/terrorism
 - Spelled out in greater detail
- Environmental impact
- Health impact
- Justice--patents, ownership
- Commerce and self-regulation

Science 15 June 2007: Vol. 316. no. 5831, p. 1557 DOI: 10.1126/science.316.5831.1557 Prev | Table of Contents | Next

News of the Week SYNTHETIC BIOLOGY: Attempt to Patent Artificial Organism Draws a Protest



An activist group's concern about maverick genome sequencer J. Craig Venter's intention to patent an entirely synthetic free-living organism has thrown a spotlight on the emerging intellectual-property landscape in this hot new field. The protesters claim that Venter wants his company to become the Microsoft of synthetic biology, dominating the industry.

Venter hopes to use the artificial life form, which he says does not yet exist, as a carrier for genes that would enable the bug to crank out hydrogen or ethanol to produce cheap energy. Duke University law professor Arti Rai says the patent, if awarded, "could be problematic" only if Venter's product became the standard in the field. But Venter says this application is just the start: He plans to patent methods that would cover more than the single microbe described in the application. "We'd certainly like the freedom to operate on all synthetic organisms" that could serve as a chassis for swapping out genes, says Venter, whose research team is at the nonprofit J. Craig Venter Institute in Rockville, Maryland, but who recently started a company to commercialize the work. Filed last October and published by the U.S. Patent and Trademark Office on 31 May, the application describes "a minimal set of protein-coding genes which provides the information required for replication of a free-living organism in a rich bacterial culture medium." The application cites work by Hamilton Smith and others on Venter's team on a simple bacterium called *Mycoplasma genitalium* that they are using to determine the minimum number of genes for life. They want to synthesize this "minimal genome" from scratch, get it working inside a cell, then add genes to produce cheap fuels (*Science*, 14 February 2003, p. <u>1006</u>). In a press release, the ETC Group, a technology watchdog in Ottawa, Canada, called Venter's "monopoly claims ... the start of a high-stakes commercial race to synthesize and privatize synthetic life forms." ETC calls for the U.S. and international patent offices to reject the patent so that societal implications can be considered. ETC also cited a recent *Newsweek* interview in which the scientist says he wants to create "the first billion- or trillion-dollar organism."

Venter says this is just one of several patent applications that would give his company, Synthetic Genomics Inc., exclusive rights to methods for making synthetic organisms. The artificial *Mycoplasma* "may or may not be" the one used to generate hydrogen or ethanol, he says; his team is working on several species. "We haven't given any thought to" the licensing conditions, but in any case, they would not impede work in academic labs, says Venter, adding, "This is a problem that we hope will have hundreds of solutions."

iGEM

Ν

H

The International Genetically Engineered Machine (iGEM) competition is a worldwide competition between teams of undergraduate, graduate and PhD students from different universities who are interested in the field of synthetic biology. When creating their projects, the teams use the BioBricks (standardized biological parts) from the iGEM registry to make new, functional biological systems. The teams come from Asia, Europe, United States and Canada to the Massachusetts Institute of Technology (MIT) in Boston to present their project.

"Synthetic Biology: ENGINEERING LIFE" IMAGINATION IS THE LIMIT





Acknowledgements



The Future of Synthetic Riology?



What are the key issues? Not these

- Misuse for weapons/terrorism
 - Any technology can be misapplied/put to pernicious use
 - Issue is into whose hands does the technology fall?
- Environmental impact
 - Can be handled through regulation
- Health impact
 - Can be handled through regulation and enforcement
- Justice--patents, ownership, commerce
 - No special issue relative to synthetic biology





analysis Modelling of complex states

BIOSYSTEMS

Engineering Nanoscale technology/metrology Electronics Process control theory Systems modelling

Defining the Rule Sets for Biological Design, Assembly and Function

- common genetic (digital) code in all life forms
- genomes encode a limited series of structural building blocks (protein motifs and programmed assembly)
- combinatorial assembly of protein building blocks generates extravagant structural and functional diversity


Ethics of new technology: dual-

use			
	"evil" Technophobic (Bill Joy)	"good" Technophilic (Ray Kurzweil)
•	Control and if necessary extinguish technology	Technology is inevitableBottom-up monitoring,	
•	Top-down monitoring and control, hierarchical, few in power (surveillance)	democratic, participatory, many in power (sourveillance)	e)
•	Philosophy of secrecy	 Proliferation of open source 	
•	Licensing, monitoring, gated access, tracking, inspection	projects (OpenWetWare, diybio, biopunk, biohack)	
•	Challenges are concentrated, government provides national security	 Challenges are distributed, citizen defense, biosensors 	

Biological warfare and public health

- Can these technologies be weaponized?
- Risk assessment
 - Access to existing samples
 - Creating pathogens is difficult
 - Superbugs (Staph aureus), emerging infections
- Simultaneous development of defenses
 - Sensors

Exploring Biospace

The Design Power of Combinatorial Interactions and Assemblies

30,000 genes

- two genes cooperate to create a function =(30,000 x 29,999)/2 = 449,985,000 potential combinations
- 100 genes generate a complex function
 =10²⁸⁹ potential combinations
- if any combination of genes can generate a function = 2 x 10^{72,403} potential combinations
- number of theoretical possibilities for synthetic assembly (biospace) far exceed narrow molecular space sampled in evolutionary time



Biological Design: "Endless Forms Most Beautiful": Limitless Diversity From Combinatorial Assemblies of Limited Building Blocks



Sequencing & synthesis follow Moore's law



Human genome sequence (2001): 10 yrs, \$ 3 billion / (2007) 2 months \$ 2 million Total synthesis of bacterial genome (2008) This paper was produced for a meeting organized by Health & Consumers DG and represents the views of its author on the subject. These views have not been adopted or in any way approved by the Commission and should not be relied upon as a statement of the Commission's or Health & Consumers DG's views. The European Commission does not guarantee the accuracy of the data included in this paper, nor does it accept responsibility for any use made thereof.